AMGNHealthcare · Drug Manufacturers - GeneralThe 34 Wall Street analysts covering Amgen, Inc. hold a median 12-month price target of $400 — -0.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 6 Oct 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Amgen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (96): The business earns solid, repeatable profits on what it owns.
Issuance (46): The company has been issuing shares or taking on financing, diluting existing holders.
Size (1): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AMGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −0.6% from it.
Of the 20 most recent actions, 7 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Sept 2026 | Scotiabank | Maintains | Sector Outperform | $450 → $500 |
| 10 Sept 2026 | HSBC | Downgrade | Hold | — |
| 10 Sept 2026 | HSBC | Downgrade | Hold | $445 → $425 |
| 8 Sept 2026 | BMO Capital | Downgrade | Market Perform | — |
| 8 Sept 2026 | BMO Capital | Downgrade | Market Perform | $450 |
| 8 Sept 2026 | Cantor Fitzgerald | Reiterates | Neutral | $400 |
| 8 Sept 2026 | Cantor Fitzgerald | Reiterates | Neutral | — |
| 4 Sept 2026 | Wells Fargo | Maintains | Equal-Weight | $400 → $435 |
| 4 Sept 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 20 Aug 2026 | Piper Sandler | Maintains | Overweight | — |
| 20 Aug 2026 | Piper Sandler | Maintains | Overweight | $427 → $457 |
| 19 Aug 2026 | Argus Research | Maintains | Buy | $375 → $460 |
| 19 Aug 2026 | Argus Research | Maintains | Buy | — |
| 19 Aug 2026 | Morgan Stanley | Maintains | Equal-Weight | $351 → $362 |
| 19 Aug 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 18 Aug 2026 | Cantor Fitzgerald | Maintains | Neutral | — |
| 18 Aug 2026 | Cantor Fitzgerald | Maintains | Neutral | $350 → $400 |
| 18 Aug 2026 | Mizuho | Maintains | Neutral | $303 → $352 |
| 18 Aug 2026 | Mizuho | Maintains | Neutral | — |
| 14 Aug 2026 | Barclays | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AMGN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 6 Oct 2026, Amgen, Inc. returned +40.8% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 30% of US stocks
Cheaper than 22% of US stocks
Cheaper than 5% of US stocks
Cheaper than 22% of US stocks
Higher than 51% of US stocks
Higher than 79% of US stocks
Higher than 84% of US stocks
Higher than 90% of US stocks
Higher than 84% of US stocks
Higher than 96% of US stocks
Higher than 90% of US stocks
Higher than 82% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Amgen, Inc. has a market value of $217.7B and an enterprise value of $261.0B.
Revenue in the twelve months to 30 June 2026: $38.1B. The latest quarter grew 9.5% year on year.
Net income over the same four quarters: $8.7B, a 23.0% net margin.
Diluted earnings per share, trailing twelve months: $16.09.
Free cash flow in the twelve months to 30 June 2026: $10.2B.
Amgen, Inc. spent $5.3B on dividends in the twelve months to 30 June 2026.
Trailing P/E: 25.0×; forward P/E: 16.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.50%, paying out 61% of earnings.
Amgen, Inc. employs 31,500 people — $1.2M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Amgen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Goldman Sachs lead U.S. biotech analyst Salveen Richter discussed biotech innovations in China and said large biopharma companies are looking at China assets.
Why it matters — The discussion concerns large biopharma companies’ interest in China assets, a topic relevant to AMGN watchers following developments in the biotech sector.
Amgen has recently drawn considerable attention from users of Zacks.com. The excerpt says investors should be aware of facts that could affect the stock’s prospects but does not specify them.
Why it matters — AMGN watchers may note the increased attention and that the article points to factors affecting the stock’s prospects, without detailing those factors in the excerpt.
The Motley Fool compares Amgen and Vertex Pharmaceuticals as potential biotech investments for 2026. Amgen is highlighted for its diversified portfolio of established oncology and inflammation therapies supported by robust cash flow, while Vertex is noted for its dominance in cystic fibrosis and expansion into gene therapies.
Why it matters — Amgen watchers would care because the piece frames the company's diversification and stable cash flow as a contrasting investment profile to Vertex's more focused, higher-growth approach.
Amgen closed at $407.27 in the latest trading session, down 3.38% from the previous day. The stock dipped while the broader market gained.
Why it matters — AMGN watchers would note the stock's decline against a rising market, which may signal specific investor concerns about the company.
Eli Lilly and Novo Nordisk presented new data at the European Association for the Study of Diabetes (EASD) meeting in Milan, renewing focus on the GLP-1/weight-loss drug market. The report also discusses exchange-traded funds that offer diversified exposure to growth in this sector.
Why it matters — The GLP-1 weight-loss drug competition between Lilly and Novo Nordisk affects the broader metabolic-disease landscape in which Amgen operates.
The 34 Wall Street analysts covering Amgen, Inc. have a median 12-month price target of $400, with estimates ranging from $225 to $500. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 34 analysts covering Amgen, Inc., 12 rate it a Buy, 17 a Hold and 5 a Sell. Ticker Nerd's systematic factor model ranks Amgen, Inc. 93 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Oct 2026, Amgen, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (96 of 100).
No one can know that. What the data says: the median 12-month target from 34 analysts implies -0.6% from the last close, and Ticker Nerd's factor model ranks Amgen, Inc. 93 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Amgen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $225 to $500 over the next 12 months.
Amgen, Inc. returned +40.8% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Amgen Inc. Common Stock represents ownership in Amgen Inc., a biotechnology company focused on discovering, developing, manufacturing, and marketing human therapeutics for serious diseases.
The most recent item we track (CNBC Television, 6 Oct 2026): "Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter". Goldman Sachs lead U.S. biotech analyst Salveen Richter discussed biotech innovations in China and said large biopharma companies are looking at China assets.
Amgen Inc. Common Stock represents ownership in Amgen Inc., a biotechnology company focused on discovering, developing, manufacturing, and marketing human therapeutics for serious diseases. The company’s portfolio spans therapies used in oncology, inflammation, cardiovascular conditions, osteoporosis, and rare diseases, making it a significant participant in global biopharmaceutical markets. Amgen also supports its business through biologic manufacturing capabilities and a commercial organization that brings prescription medicines to patients and healthcare providers in multiple regions. As a large-cap healthcare equity, Amgen Inc. Common Stock is widely followed by market participants for its role in the biotechnology sector and its exposure to branded medicines, biologics, and specialty treatment areas.
CEO Mr. Robert A. Bradway · 31,500 employees · United States · https://www.amgen.com
